(Q28264038)

0 references

Sanna Herrgard

0 references

Daniel K Treiber

0 references

Paul Gallant

0 references

Corey E Atteridge

0 references

Brian T Campbell

0 references

Katrina W Chan

0 references

Pietro Ciceri

0 references

Mindy I Davis

0 references

Philip T Edeen

0 references

Raffaella Faraoni

0 references

Mark Floyd

0 references

Jeremy P Hunt

0 references

Daniel J Lockhart

0 references

Zdravko V Milanov

0 references

Michael J Morrison

0 references

Gabriel Pallares

0 references

Hitesh K Patel

0 references

Stephanie Pritchard

0 references

Lisa M Wodicka

0 references

Patrick P Zarrinkar

Targeting tyrosine kinases in cancer: the second wave

0 references

language of work or name

English

0 references

publication date

January 2008

0 references

0 references

0 references

0 references

127-32

0 references

cites work

1 reference

7 January 2021

Mechanisms of drug inhibition of signalling molecules

1 reference

7 January 2021

The second wave in kinase cancer drugs

1 reference

7 January 2021

Features of selective kinase inhibitors

1 reference

7 January 2021

The specificities of protein kinase inhibitors: an update

1 reference

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

7 January 2021

The protein kinase complement of the human genome

1 reference

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

7 January 2021

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

7 January 2021

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

1 reference

7 January 2021

Design and discovery of small molecules targeting raf-1 kinase

1 reference

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

7 January 2021

Sorafenib in renal cell carcinoma

1 reference

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

7 January 2021

Molecular basis for specificity in the druggable kinome: sequence-based analysis

1 reference

7 January 2021

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

1 reference

7 January 2021

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

1 reference

7 January 2021

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

1 reference

7 January 2021

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

1 reference

7 January 2021

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

1 reference

7 January 2021

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

1 reference

7 January 2021

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

1 reference

7 January 2021

Roscovitine targets, protein kinases and pyridoxal kinase

1 reference

7 January 2021

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

1 reference

7 January 2021

An efficient rapid system for profiling the cellular activities of molecular libraries.

1 reference

7 January 2021

High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding

1 reference

7 January 2021

Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases

1 reference

7 January 2021